Lobe Sciences Ltd. (LOBE.CN)
Lobe Sciences Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.08, up 3.13% on the session, giving a market capitalisation of $23.4M. Its beta of -0.06 implies it has historically moved less than the broad market.
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Lobe Sciences Ltd. is most often compared with the following Healthcare names: